Tilray Q1 revenue jumps 23%, but beverage surge may be pre-ban pull-forward

What happened

Tilray reported record Q1 FY2027 revenue of $257.1 million, up 23% year-over-year, with gross profit up 35% to $77.5 million and gross margin expanding to 30% from 27%. The growth was driven by strong performance in beverages and international markets, reversing the beverage segment's prior revenue declines seen in Q2 FY26. However, the beverage surge likely includes pre-ban stocking of hemp-derived THC drinks ahead of the U.S. federal 0.4 mg THC cap effective November 2026, which clouds sustainability. International cannabis continues to scale, but the company remains unprofitable with a history of cash burn and equity dilution. The improvement is positive but does not resolve the core regulatory and profitability overhangs.

Implication

In the short term, the strong Q1 print may buoy sentiment and support the stock near the lower end of the base case range, but trading volatility is likely to persist around the November hemp cap implementation. Over the next two quarters, investors should scrutinize whether beverage revenue remains resilient without HD-9 products and whether international cannabis growth can offset any downturn. The expanded gross margin suggests improving mix, but absolute profitability and cash flow remain weak, with adjusted EBITDA still far below levels needed to justify a higher valuation. If management can deliver FY27 adjusted EBITDA in line with the raised revenue base and keep operating cash flow near breakeven, the stock could trade toward $10-12. Conversely, any relapse in beverage margins or cash burn would push the stock back toward the bear case of $6.

Thesis delta

The new report shifts the thesis modestly positive on near-term execution, as revenue growth and margin expansion exceed the prior base case assumptions, but introduces a new risk that beverage growth is partially a pull-forward ahead of the U.S. hemp THC ban. The overall WAIT rating remains appropriate because the company's structural profitability and cash generation challenges are unchanged, and the regulatory overhang on hemp beverages will be tested within weeks. A sustained move toward the bull case requires confirmation that international cannabis can carry the growth without beverage and that adjusted EBITDA scales toward the $70M+ level.